Novo Nordisk Cuts Wegovy Price for Uninsured Patients to $499 Monthly

The move follows the FDA's declaration ending a semaglutide shortage and aims to compete with compounded alternatives and rival Eli Lilly's offerings.

Novo Nordisk has launched NovoCare, a pharmacy service offering Wegovy at $499 per month for patients without insurance or obesity medication coverage.
This pricing is significantly lower than Wegovy's $1,349 list price but remains more expensive than compounded alternatives, which cost less than half as much.
The FDA recently declared the end of a two-year semaglutide shortage, prompting Novo Nordisk to target consumers who previously turned to compounded weight-loss drugs.
Rival Eli Lilly has implemented a similar direct-pay program for its weight-loss drug Zepbound, with starting doses priced at $349 per month.
Novo Nordisk’s stock rose 4% following the announcement, while shares of compounding pharmacy players like Hims & Hers fell sharply.